13F filer · CIK 2104501
Remedium Capital Partners, LLC
WEST PALM BEACH, FL · filing since Q4 2025 · last filing Aug 7, 2026
Reported value
$451.6M
+$170.5M vs prior
Positions
6
New / sold out
1 / 1
Added / reduced
2 / 0
Turnover
1.8%
buys $7.6M · sells $6.6M
Top-10 weight
100.0%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Crescent Biopharma Inc | +361,250 | – | +$6.5M |
| Added | Spyre Therapeutics Inc | +7,938 | +0.5% | +$704.7K |
| Added | Apogee Therapeutics Inc | +3,100 | +0.5% | +$411.5K |
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Crescent Biopharma Inc | -361,250 | -100.0% | $-6.6M |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Oruka Therapeutics IncCOM | 1,565,661 | $149.0M | 32.99% |
| 2 | Spyre Therapeutics IncCOM | 1,464,169 | $130.0M | 28.78% |
| 3 | Apogee Therapeutics IncCOM | 586,691 | $77.9M | 17.24% |
| 4 | Damora Therapeutics IncCOM | 2,045,473 | $53.2M | 11.78% |
| 5 | Jade Biosciences IncCOM | 1,577,750 | $35.1M | 7.76% |
| 6 | Crescent Biopharma IncCOM | 361,250 | $6.5M | 1.44% |